NCT03203876 2022-03-10A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid TumorsBristol-Myers SquibbPhase 1 Completed10 enrolled